Sigrid Therapeutics appoints internationally established consumer industry executive Mattias Ankarberg as Chairman
Company aims to capitalize on new health and wellbeing market opportunities for SiPore® supplements
Stockholm, Sweden October 24th October, 2022. Sigrid Therapeutics, a Swedish consumer health tech company, today announced that it has appointed Mattias Ankarberg as Chairman of the Board. Mattias has a long and successful career in the international retail and consumer goods industry. He is currently CEO of publicly listed Byggmax Group and board member of Thule Group, and has previously spent many years with H&M, most recently as Global Head of Sales & Marketing, and with McKinsey & Company, based in Sweden and the US. Sigrid views Ankarberg’s vast experience from the consumer industry as ideal to help explore the commercialization of its SiPore® platform into the food supplement, oral health and veterinary markets.
Sigrid Therapeutics is a privately-held consumer focused health tech company driven by the vision that no one should fall sick with chronic lifestyle diseases such as type 2 diabetes and obesity. Sigrid has developed and patented a unique silica-based platform technology, SiPore®, that limits the breakdown of foods in the gut, thereby enabling lower blood sugar and lipids levels. SiPore® can be used to target a range of metabolic disorders and diseases, and the first product SiPore21® is clinically proven to lower blood sugar (HbA1c), cholesterol and body fat in prediabetics and early-stage type 2 diabetics.
– Sigrid is now entering an exciting phase of commercial development. In addition to our core development of a medical device for diabetes prevention, we have identified several other major application areas for our patented technology – including dietary supplements, oral health and veterinary products - and have business plans for each. The experience and knowledge of the consumer and retail sector that Mattias brings are invaluable in successfully bringing our commercial plans forward, says Sana Ajamovic, Sigrid’s Co-Founder and CEO.
– I have followed Sigrid’s rapid progress and am now delighted to join Sigrid and contribute to the growth through my experience, including driving international expansion, establish e-commerce and realizing new ideas. I look forward to together with the founders, board members and dedicated team move Sigrid closer to realizing both the vision and what is a clear near-term commercial potential, adds Mattias Ankarberg.
For more information, please contact:
Sana Alajmovic, Co-Founder & CEO, Sigrid Therapeutics
Phone +46 72 389 3396
Email: sana@sigridthx.com
Mattias Ankarberg, Chairman Sigrid Therapeutics
Phone: +46 70 796 3831
Email: mattias@sigridthx.com
About Mesoporous silica particles (MSP)
Mesoporous silica particles (MSP) are a type of ingestible synthetic amorphous silica particles that can be produced with a large surface area and a range of pore sizes. Studies in mice, published in Nanomedicine1 have shown that food efficiency was reduced by 33% leading to a positive effect on metabolic profile with significant lower levels of adipose tissue formation and leptin, together with lower levels of circulating insulin. Weight gain was thus sufficiently attenuated. Additional pre-clinical results published in Advanced Healthcare Materials2 confirm these findings and are compatible with a mode of action whereby a portion of the enzymes are trapped inside the MSPs resulting in an enzyme-blocking effect reducing the break down food and thus reduce the energy uptake into the body.
About Sigrid Therapeutics
Sigrid Therapeutics (Sigrid) is a clinical-stage consumer oriented health tech pioneering a new class of engineered materials to prevent and treat metabolic disease and disorders, including type 2 diabetes. The Company’s lead product candidate, SiPore21®, is an orally-administered medical evice based on the Company’s proprietary platform technology, SiPore®. Designed to act locally in the gut, SiPore21®, consists of precisely engineered micron-sized silica particles with tailored porosity. Clinical data confirms the beneficial effects on SiPore21® on a range of metabolic parameters and its excellent safety profile3. Upon its approval, SiPore21®, will be the first medical treatment available for reduction of blood sugar levels in people at risk of developing type 2 diabetes. https://www.sigridthx.com/.
References
- Mesoporous Silica with Precisely Controlled Pores Reduces Food Efficiency and Suppresses Weight Gain in Mice: Mia Rinde, et al. https://www.futuremedicine.com/doi/10.2217/nnm-2019-0262
- Entrapping Digestive Enzymes with Engineered Mesoporous Silica Particles Reduces Metabolic Risk Factors in Humans: Erik R. Waara, et.al. https://onlinelibrary.wiley.com/doi/10.1002/adhm.202000057
- Engineered mesoporous silica reduces long-term blood glucose, HbA1c, and improves metabolic parameters in prediabetics: Jeanha Baek, et.al. https://www.futuremedicine.com/doi/10.2217/nnm-2021-0235
